Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

Purpose: Monoclonal antibodies (mAb) that block programmed death (PD)-1 or cytotoxic T lymphocyte antigen (CTLA-4) receptors have been associated with durable clinical responses against a variety of cancer types and hold great potential as novel cancer therapeutics. Recent evidence suggest that targeted blockade of multiple immunosuppressive pathways can induce synergistic antitumor responses. Experimental Design: In this study, we investigated whether targeted blockade of CD73, an ectonucleotidase that catabolizes the hydrolysis of extracellular adenosine monophosphate (AMP) to adenosine, can enhance the antitumor activity of anti-CTLA-4 and anti-PD-1 mAbs against transplanted and chemically induced mouse tumors. Results: Anti-CD73 mAb significantly enhanced the activity of both anti-CTLA-4 and anti-PD-1 mAbs against MC38-OVA (colon) and RM-1 (prostate) subcutaneous tumors, and established metastatic 4T1.2 breast cancer. Anti-CD73 mAb also significantly enhanced the activity of anti-PD-1 mAb against 3-methylcholanthrene (MCA)-induced fibrosarcomas. Gene-targeted mice revealed that single-agent therapies and combinatorial treatments were dependent on host IFN-γ and CD8+ T cells, but independent of perforin. Interestingly, anti-CD73 mAb preferentially synergized with anti-PD-1 mAb. We investigated the effect of extracellular adenosine on tumor-infiltrating T cells and showed that activation of A2A adenosine receptor enhances PD-1 expression, but not CTLA-4 expression, on tumor-specific CD8+ T cells and CD4+ Foxp3+ T regulatory cells. Conclusions: Taken together, our study revealed that targeted blockade of CD73 can enhance the therapeutic activity of anti-PD-1 and anti-CTLA-4 mAbs and may thus potentiate therapeutic strategies targeting immune checkpoint inhibitors in general. Clin Cancer Res; 19(20); 5626–35. ©2013 AACR.

[1]  A. Belldegrun,et al.  Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer , 2015 .

[2]  J. Wolchok,et al.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.

[3]  S. Loi,et al.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer , 2013, Proceedings of the National Academy of Sciences.

[4]  C. Horak,et al.  Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). , 2013 .

[5]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Martin Turcotte,et al.  CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth , 2012, Journal of biomedicine & biotechnology.

[7]  P. Hwu,et al.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. , 2012, Cancer research.

[8]  Xiaojian Wu,et al.  High expression of CD73 as a poor prognostic biomarker in human colorectal cancer , 2012, Journal of surgical oncology.

[9]  H. Dolstra,et al.  Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. , 2012, Blood.

[10]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[11]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[12]  A. Möller,et al.  CD73-deficient mice are resistant to carcinogenesis. , 2012, Cancer research.

[13]  M. Smyth,et al.  CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.

[14]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[15]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[16]  J. N. van den Anker,et al.  Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development: A Clinician's Request for a More Integrated Approach , 2012, Journal of biomedicine & biotechnology.

[17]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[18]  Y. Najjar,et al.  Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms , 2011, European journal of immunology.

[19]  T. Curiel,et al.  CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. , 2011, The Journal of clinical investigation.

[20]  E. Wherry.  T cell exhaustion , 2011, Nature Immunology.

[21]  H. V. van Boven,et al.  Overall survival and PD‐L1 expression in metastasized malignant melanoma , 2011, Cancer.

[22]  M. Smyth,et al.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. , 2011, Cancer research.

[23]  M. Smyth,et al.  CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. , 2011, Cancer research.

[24]  S. Loi,et al.  Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy , 2011, Proceedings of the National Academy of Sciences.

[25]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[26]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[27]  M. Smyth,et al.  Extracellular adenosine triphosphate and adenosine in cancer , 2010, Oncogene.

[28]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[29]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[30]  P. Hwu,et al.  Treating cancer by targeting the immune system. , 2010, The New England journal of medicine.

[31]  T. Whiteside.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression , 2010, Expert opinion on biological therapy.

[32]  T. Curiel,et al.  CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. , 2010, Cancer research.

[33]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[34]  M. Smyth,et al.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis , 2010, Proceedings of the National Academy of Sciences.

[35]  Loise M. Francisco,et al.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.

[36]  J. Weber.  Ipilimumab: controversies in its development, utility and autoimmune adverse events , 2009, Cancer Immunology, Immunotherapy.

[37]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[38]  B. Kavanagh,et al.  Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. , 2009, Cancer research.

[39]  A. Ohta,et al.  Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia , 2008, Clinical Cancer Research.

[40]  M. Sayegh,et al.  Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells , 2008, Proceedings of the National Academy of Sciences.

[41]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[42]  R. Thompson,et al.  Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine1 , 2007, The Journal of Immunology.

[43]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[44]  S. Quezada,et al.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.

[45]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[47]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[48]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[49]  J. Blay,et al.  The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. , 1997, Cancer research.

[50]  C. Liu,et al.  Microenvironment and Immunology PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-g Inducible Chemokines , 2012 .

[51]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .